"ASSOCIATION_TYPE"	"PMID"	"NUM_SENTENCE"	"ENTITY1_TEXT"	"ENTITY1_INI"	"ENTITY1_END"	"ENTITY1_TYPE"	"ENTITY2_TEXT"	"ENTITY2_INI"	"ENTITY2_END"	"ENTITY2_TYPE"	"SENTENCE"
"PA"	17897305	8	"venous thrombosis"	53	70	"Diseases & Disorders"	"oral contraceptives"	106	125	"Chemicals & Drugs"	"Body height, weight and obesity increase the risk of venous thrombosis, especially obesity in women using oral contraceptives."
"FA"	18042885	0	"Cardiovascular thromboembolic adverse effects"	0	45	"Diseases & Disorders"	"cyclooxygenase"	62	76	"Chemicals & Drugs"	"Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs."
"FA"	18042885	0	"Cardiovascular thromboembolic adverse effects"	0	45	"Diseases & Disorders"	"nonselective antiinflammatory drugs"	104	139	"Chemicals & Drugs"	"Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs."
"FA"	18037672	8	"motion sickness"	180	195	"Diseases & Disorders"	"alfentanil"	58	68	"Chemicals & Drugs"	"The frequency of PONV did not correlate to the amounts of alfentanil, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or motion sickness."
"FA"	18037672	8	"motion sickness"	180	195	"Diseases & Disorders"	"propofol"	70	78	"Chemicals & Drugs"	"The frequency of PONV did not correlate to the amounts of alfentanil, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or motion sickness."
"PA"	17237684	13	"dry eye"	187	194	"Diseases & Disorders"	"botulinum toxin"	41	56	"Chemicals & Drugs"	"However, decreased tear production after botulinum toxin injection for crow's feet is a possible complication and patients should be advised of the small but definite risk of a temporary dry eye."
"PA"	17940253	1	"neurological disorders"	61	83	"Diseases & Disorders"	"Botulinum toxins"	0	16	"Chemicals & Drugs"	"Botulinum toxins are potent neurotoxins used in a variety of neurological disorders."
"PA"	17940253	3	"spasticity"	97	107	"Diseases & Disorders"	"botulinum toxin type B"	113	135	"Chemicals & Drugs"	"We describe the case of a 10-year-old boy who developed systemic weakness following treatment of spasticity with botulinum toxin type B."
"PA"	17940253	3	"systemic weakness"	56	73	"Diseases & Disorders"	"botulinum toxin type B"	113	135	"Chemicals & Drugs"	"We describe the case of a 10-year-old boy who developed systemic weakness following treatment of spasticity with botulinum toxin type B."
"FA"	17274718	2	"gingival overgrowth"	158	177	"Diseases & Disorders"	"CsA"	145	148	"Chemicals & Drugs"	"Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with cyclosporin A (CsA)-induced gingival overgrowth."
"FA"	17274718	6	"periodontitis"	128	141	"Diseases & Disorders"	"CsA"	63	66	"Chemicals & Drugs"	"ET-1 mRNA expression was significantly higher in patients with CsA-induced gingival overgrowth (P <0.001) than in patients with periodontitis and the controls."
"PA"	17274718	6	"gingival overgrowth"	75	94	"Diseases & Disorders"	"CsA"	63	66	"Chemicals & Drugs"	"ET-1 mRNA expression was significantly higher in patients with CsA-induced gingival overgrowth (P <0.001) than in patients with periodontitis and the controls."
"PA"	17274718	9	"gingival overgrowth"	107	126	"Diseases & Disorders"	"CsA"	95	98	"Chemicals & Drugs"	"These results suggest that CsA can modulate the expression of ET-1 in gingival fibroblasts and CsA-induced gingival overgrowth."
"FA"	17274718	2	"periodontitis"	91	104	"Diseases & Disorders"	"CsA"	145	148	"Chemicals & Drugs"	"Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with cyclosporin A (CsA)-induced gingival overgrowth."
"PA"	17274718	2	"gingival overgrowth"	158	177	"Diseases & Disorders"	"cyclosporin A"	130	143	"Chemicals & Drugs"	"Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with cyclosporin A (CsA)-induced gingival overgrowth."
"PA"	18640477	10	"mild asthma"	95	106	"Diseases & Disorders"	"montelukast"	27	38	"Chemicals & Drugs"	"The evidence suggests that montelukast is an effective monotherapy controller in children with mild asthma."
"FA"	18640477	0	"mild asthma"	78	89	"Diseases & Disorders"	"montelukast"	28	39	"Chemicals & Drugs"	"Review of recent results of montelukast use as a monotherapy in children with mild asthma."
"FA"	18640477	5	"mild asthma"	92	103	"Diseases & Disorders"	"montelukast"	117	128	"Chemicals & Drugs"	"This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with montelukast, a leukotriene receptor antagonist that is approved for the treatment of asthma and allergic rhinitis in children and adults."
"PA"	18640477	6	"mild asthma"	235	246	"Diseases & Disorders"	"montelukast"	171	182	"Chemicals & Drugs"	"A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, montelukast, leukotriene receptor antagonist, pediatric asthma, mild asthma, exercise-induced asthma, and bronchoconstriction."
"PA"	18640477	9	"asthma"	151	157	"Diseases & Disorders"	"montelukast"	105	116	"Chemicals & Drugs"	"The results from these studies, encompassing end points measuring lung function and symptoms, found that montelukast provided effective and beneficial asthma control to children aged 2 to 14 years with mild asthma."
"PA"	18640477	5	"allergic rhinitis"	213	230	"Diseases & Disorders"	"montelukast"	117	128	"Chemicals & Drugs"	"This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with montelukast, a leukotriene receptor antagonist that is approved for the treatment of asthma and allergic rhinitis in children and adults."
"PA"	18953065	12	"leukoencephalopathy"	115	134	"Diseases & Disorders"	"procarbazine"	38	50	"Chemicals & Drugs"	"The combination of high-dose MTX with procarbazine and CCNU is feasible and effective and results in a low rate of leukoencephalopathy."
"PA"	18953065	12	"leukoencephalopathy"	115	134	"Diseases & Disorders"	"high-dose MTX"	19	32	"Chemicals & Drugs"	"The combination of high-dose MTX with procarbazine and CCNU is feasible and effective and results in a low rate of leukoencephalopathy."
"PA"	18953065	12	"leukoencephalopathy"	115	134	"Diseases & Disorders"	"CCNU"	55	59	"Chemicals & Drugs"	"The combination of high-dose MTX with procarbazine and CCNU is feasible and effective and results in a low rate of leukoencephalopathy."
"PA"	18434457	12	"anterior shoulder dislocation"	66	95	"Diseases & Disorders"	"Intra-articular injection of lidocaine"	0	38	"Chemicals & Drugs"	"Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and diazepam."
"PA"	18434457	12	"pain"	114	118	"Diseases & Disorders"	"intravenous meperidine"	129	151	"Chemicals & Drugs"	"Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and diazepam."
"PA"	18434457	12	"pain"	114	118	"Diseases & Disorders"	"diazepam"	156	164	"Chemicals & Drugs"	"Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and diazepam."
"PA"	18434457	12	"anterior shoulder dislocation"	66	95	"Diseases & Disorders"	"diazepam"	156	164	"Chemicals & Drugs"	"Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and diazepam."
"PA"	18434457	12	"anterior shoulder dislocation"	66	95	"Diseases & Disorders"	"intravenous meperidine"	129	151	"Chemicals & Drugs"	"Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and diazepam."
"PA"	18434457	8	"pain"	5	9	"Diseases & Disorders"	"intra-articular lidocaine"	87	112	"Chemicals & Drugs"	"Mean pain (mm) recorded before injection, before reduction, and after reduction in the intra-articular lidocaine group was 84.3 (95% confidence interval (CI) 79.8 to 88.8), 52.6 (95% CI 45.2 to 60.1), and 27.3 (95% CI 19.9 to 34.7), respectively."
"PA"	18434457	12	"pain"	114	118	"Diseases & Disorders"	"Intra-articular injection of lidocaine"	0	38	"Chemicals & Drugs"	"Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and diazepam."
"FA"	18371953	4	"glioma"	138	144	"Diseases & Disorders"	"indomethacin-loaded nanocapsules"	53	85	"Chemicals & Drugs"	"The aim of this study was to evaluate the effects of indomethacin-loaded nanocapsules and indomethacin ethyl ester-loaded nanocapsules on glioma cell lines."
"PA"	18371953	11	"glioma"	178	184	"Diseases & Disorders"	"indomethacin-loaded nanocapsules"	93	125	"Chemicals & Drugs"	"Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, in glioma cells was not observed in the organotypic cultures, indicating selective cytotoxicity of those formulations for tumoral cells."
"PA"	18371953	0	"glioma"	96	102	"Diseases & Disorders"	"indomethacin"	26	38	"Chemicals & Drugs"	"Selective cytotoxicity of indomethacin and indomethacin ethyl ester-loaded nanocapsules against glioma cell lines: an in vitro study."
"PA"	18371953	7	"glioma"	193	199	"Diseases & Disorders"	"indomethacin-loaded nanocapsules"	46	78	"Chemicals & Drugs"	"The main finding of the present study is that indomethacin-loaded nanocapsules formulation was more potent than a solution of indomethacin in decreasing the viability and cell proliferation of glioma lines."
"PA"	18371953	7	"glioma"	193	199	"Diseases & Disorders"	"solution of indomethacin"	114	138	"Chemicals & Drugs"	"The main finding of the present study is that indomethacin-loaded nanocapsules formulation was more potent than a solution of indomethacin in decreasing the viability and cell proliferation of glioma lines."
"PA"	18371953	9	"glioma"	22	28	"Diseases & Disorders"	"indomethacin ethyl ester-loaded nanocapsules"	100	144	"Chemicals & Drugs"	"In addition, when the glioma cells were exposed to 25 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, a necrotic cell death was observed."
"FA"	18371953	0	"glioma"	96	102	"Diseases & Disorders"	"indomethacin ethyl ester-loaded nanocapsules"	43	87	"Chemicals & Drugs"	"Selective cytotoxicity of indomethacin and indomethacin ethyl ester-loaded nanocapsules against glioma cell lines: an in vitro study."
"PA"	18371953	9	"glioma"	22	28	"Diseases & Disorders"	"indomethacin-loaded nanocapsules"	64	96	"Chemicals & Drugs"	"In addition, when the glioma cells were exposed to 25 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, a necrotic cell death was observed."
"PA"	18371953	11	"glioma"	178	184	"Diseases & Disorders"	"indomethacin ethyl ester-loaded nanocapsules"	129	173	"Chemicals & Drugs"	"Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, in glioma cells was not observed in the organotypic cultures, indicating selective cytotoxicity of those formulations for tumoral cells."
"PA"	18371953	12	"glioma"	37	43	"Diseases & Disorders"	"indomethacin ethyl ester-loaded nanocapsules"	140	184	"Chemicals & Drugs"	"Further investigations using in vivo glioma model should be helpful to confirm the distinct effects of indomethacin-loaded nanocapsules and indomethacin ethyl ester-loaded nanocapsules, in normal versus tumoral cells."
"PA"	18371953	4	"glioma"	138	144	"Diseases & Disorders"	"indomethacin ethyl ester-loaded nanocapsules"	90	134	"Chemicals & Drugs"	"The aim of this study was to evaluate the effects of indomethacin-loaded nanocapsules and indomethacin ethyl ester-loaded nanocapsules on glioma cell lines."
"PA"	18371953	8	"glioma"	134	140	"Diseases & Disorders"	"indomethacin ethyl ester"	17	41	"Chemicals & Drugs"	"Indomethacin and indomethacin ethyl ester associated together in the same nanocapsule formulation caused a synergic effect decreasing glioma cell proliferation."
"PA"	18371953	8	"glioma"	134	140	"Diseases & Disorders"	"Indomethacin"	0	12	"Chemicals & Drugs"	"Indomethacin and indomethacin ethyl ester associated together in the same nanocapsule formulation caused a synergic effect decreasing glioma cell proliferation."
"PA"	18371953	10	"glioma"	136	142	"Diseases & Disorders"	"indomethacin-loaded nanocapsules"	27	59	"Chemicals & Drugs"	"Interestingly, 5 microM of indomethacin-loaded nanocapsules was able to cause an antiproliferative effect without promoting necrosis in glioma cells."
"PA"	18371953	12	"glioma"	37	43	"Diseases & Disorders"	"indomethacin-loaded nanocapsules"	103	135	"Chemicals & Drugs"	"Further investigations using in vivo glioma model should be helpful to confirm the distinct effects of indomethacin-loaded nanocapsules and indomethacin ethyl ester-loaded nanocapsules, in normal versus tumoral cells."
"PA"	17483062	0	"visceral varicella-zoster infection"	84	119	"Diseases & Disorders"	"intravenous acyclovir"	137	158	"Chemicals & Drugs"	"Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir."
"PA"	17483062	1	"visceral varicella-zoster virus"	74	105	"Diseases & Disorders"	"intravenous acyclovir"	211	232	"Chemicals & Drugs"	"We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV)."
"PA"	17483062	1	"VZV) infection"	107	121	"Diseases & Disorders"	"intravenous acyclovir"	211	232	"Chemicals & Drugs"	"We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV)."
"SA"	18220495	3	"refractory childhood-onset schizophrenia"	131	171	"Diseases & Disorders"	"clozapine"	183	192	"Chemicals & Drugs"	"Available studies in the literature using clozapine in the pediatric population are summarized and the NIMH experience in treating refractory childhood-onset schizophrenia cases with clozapine is discussed."
"PA"	18220495	1	"treatment-resistant schizophrenia"	55	88	"Diseases & Disorders"	"clozapine"	21	30	"Chemicals & Drugs"	"Although the role of clozapine is well established for treatment-resistant schizophrenia, it is rarely used in pediatric populations, mainly due to its potentially serious adverse effects."
"PA"	18220495	2	"schizophrenia"	77	90	"Diseases & Disorders"	"clozapine"	41	50	"Chemicals & Drugs"	"To summarize practical aspects of use of clozapine in treating children with schizophrenia and management of associated adverse effects."
"PA"	18220495	4	"refractory schizophrenia"	150	174	"Diseases & Disorders"	"clozapine"	59	68	"Chemicals & Drugs"	"Despite a higher incidence of adverse effects in children, clozapine appears to be a uniquely beneficial second-line agent for treating children with refractory schizophrenia."
"PA"	17976209	0	"Keratoacanthoma"	0	15	"Diseases & Disorders"	"red dye of a tattoo"	37	56	"Chemicals & Drugs"	"Keratoacanthoma occurring within the red dye of a tattoo."
"FA"	18300089	7	"ocular inflammation"	155	174	"Diseases & Disorders"	"antimetabolites"	12	27	"Chemicals & Drugs"	"Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 ocular inflammation patients at five tertiary centers over up to 30 years."
"SA"	18300089	11	"fatal cancer"	159	171	"Diseases & Disorders"	"immunosuppressive drugs"	75	98	"Chemicals & Drugs"	"Information from the SITE Cohort Study should clarify whether use of these immunosuppressive drugs for ocular inflammation increases the risk of mortality and fatal cancer."
"PA"	18300089	10	"fatal malignancy"	48	64	"Diseases & Disorders"	"antimetabolites"	120	135	"Chemicals & Drugs"	"Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents."
"FA"	18300089	7	"ocular inflammation"	155	174	"Diseases & Disorders"	"alkylating agents"	48	65	"Chemicals & Drugs"	"Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 ocular inflammation patients at five tertiary centers over up to 30 years."
"FA"	18300089	7	"ocular inflammation"	155	174	"Diseases & Disorders"	"T-cell inhibitors"	29	46	"Chemicals & Drugs"	"Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 ocular inflammation patients at five tertiary centers over up to 30 years."
"PA"	18300089	10	"fatal malignancy"	48	64	"Diseases & Disorders"	"T-cell inhibitors"	149	166	"Chemicals & Drugs"	"Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents."
"FA"	18300089	11	"ocular inflammation"	103	122	"Diseases & Disorders"	"immunosuppressive drugs"	75	98	"Chemicals & Drugs"	"Information from the SITE Cohort Study should clarify whether use of these immunosuppressive drugs for ocular inflammation increases the risk of mortality and fatal cancer."
"FA"	18300089	7	"ocular inflammation"	155	174	"Diseases & Disorders"	"immunosuppressives"	77	95	"Chemicals & Drugs"	"Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 ocular inflammation patients at five tertiary centers over up to 30 years."
"PA"	18300089	10	"fatal malignancy"	48	64	"Diseases & Disorders"	"alkylating agents"	184	201	"Chemicals & Drugs"	"Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents."
"PA"	18923587	8	"miosis"	34	40	"Diseases & Disorders"	"Garcinia kola nut extract"	74	99	"Chemicals & Drugs"	"There were consistent significant miosis in the right eyes with instilled Garcinia kola nut extract compared to the left eyes at 15, 30 and 45 minutes (p=0.0000)."
"PA"	18342498	1	"asthma"	105	111	"Diseases & Disorders"	"ICSs"	66	70	"Chemicals & Drugs"	"There is evidence in the literature that inhaled corticosteroids (ICSs) are safe for pregnant women with asthma and their infants."
"PA"	18342498	1	"asthma"	105	111	"Diseases & Disorders"	"inhaled corticosteroids"	41	64	"Chemicals & Drugs"	"There is evidence in the literature that inhaled corticosteroids (ICSs) are safe for pregnant women with asthma and their infants."
"FA"	18452197	6	"dysplasias"	191	201	"Diseases & Disorders"	"DSS"	213	216	"Chemicals & Drugs"	"An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively)."
"FA"	18452197	6	"colonic dysplasias"	63	81	"Diseases & Disorders"	"DSS"	213	216	"Chemicals & Drugs"	"An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively)."
"FA"	18452197	0	"colitis"	138	145	"Diseases & Disorders"	"azoxymethane"	94	106	"Chemicals & Drugs"	"5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis."
"PA"	18452197	0	"colitis-associated colorectal dysplasias"	31	71	"Diseases & Disorders"	"5-aminosalicylic acid"	0	21	"Chemicals & Drugs"	"5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis."
"PA"	18452197	2	"colitis-associated neoplasia"	138	166	"Diseases & Disorders"	"dextran sulfate sodium"	101	123	"Chemicals & Drugs"	"The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia."
"SA"	18452197	9	"colitis-associated dysplasias"	72	101	"Diseases & Disorders"	"low-dose 5-ASA"	24	38	"Chemicals & Drugs"	"These data suggest that low-dose 5-ASA may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with ulcerative colitis."
"SA"	18452197	9	"colonic neoplasms"	179	196	"Diseases & Disorders"	"low-dose 5-ASA"	24	38	"Chemicals & Drugs"	"These data suggest that low-dose 5-ASA may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with ulcerative colitis."
"SA"	18452197	9	"ulcerative colitis"	214	232	"Diseases & Disorders"	"low-dose 5-ASA"	24	38	"Chemicals & Drugs"	"These data suggest that low-dose 5-ASA may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with ulcerative colitis."
"SA"	18452197	1	"colitis-associated colorectal cancer"	87	123	"Diseases & Disorders"	"5-ASA"	64	69	"Chemicals & Drugs"	"The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for colitis-associated colorectal cancer remains controversial."
"FA"	18452197	2	"colitis-associated neoplasia"	138	166	"Diseases & Disorders"	"azoxymethane"	82	94	"Chemicals & Drugs"	"The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia."
"FA"	18452197	7	"polypoid dysplasias"	177	196	"Diseases & Disorders"	"5-ASA"	27	32	"Chemicals & Drugs"	"Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively)."
"PA"	18452197	7	"tumor"	198	203	"Diseases & Disorders"	"5-ASA"	27	32	"Chemicals & Drugs"	"Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively)."
"PA"	18452197	6	"dysplasias"	191	201	"Diseases & Disorders"	"5-ASA"	153	158	"Chemicals & Drugs"	"An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively)."
"PA"	18452197	7	"flat dysplasias"	73	88	"Diseases & Disorders"	"5-ASA"	27	32	"Chemicals & Drugs"	"Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively)."
"FA"	18452197	2	"colitis-associated neoplasia"	138	166	"Diseases & Disorders"	"DSS"	125	128	"Chemicals & Drugs"	"The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia."
"PA"	18452197	6	"colonic dysplasias"	63	81	"Diseases & Disorders"	"5-ASA"	153	158	"Chemicals & Drugs"	"An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively)."
"PA"	17167348	0	"Spinal cord infarction"	0	22	"Diseases & Disorders"	"cocaine"	36	43	"Chemicals & Drugs"	"Spinal cord infarction secondary to cocaine use."
"PA"	17167348	8	"cerebrovascular events"	33	55	"Diseases & Disorders"	"Cocaine"	0	7	"Chemicals & Drugs"	"Cocaine abuse is associated with cerebrovascular events; spinal cord effects are rarely reported."
"PA"	17167348	11	"spinal cord infarction"	43	65	"Diseases & Disorders"	"cocaine"	19	26	"Chemicals & Drugs"	"Although uncommon, cocaine abuse can cause spinal cord infarction."
"SA"	17340045	1	"sarcoidosis"	55	66	"Diseases & Disorders"	"etanercept"	87	97	"Chemicals & Drugs"	"We report two rheumatoid arthritis patients developing sarcoidosis possibly induced by etanercept."
"FA"	17340045	9	"noninfectious granulomatous syndromes"	37	74	"Diseases & Disorders"	"etanercept"	97	107	"Chemicals & Drugs"	"Recently, there have been reports of noninfectious granulomatous syndromes in patients receiving etanercept for a variety of diseases."
"FA"	17340045	0	"sarcoidosis"	15	26	"Diseases & Disorders"	"etanercept"	30	40	"Chemicals & Drugs"	"Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients."
"FA"	17340045	0	"rheumatoid arthritis"	49	69	"Diseases & Disorders"	"etanercept"	30	40	"Chemicals & Drugs"	"Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients."
"FA"	17340045	5	"erythema nodosum"	20	36	"Diseases & Disorders"	"etanercept"	90	100	"Chemicals & Drugs"	"The other developed erythema nodosum and a plaque lesion on the right arm after 1 year of etanercept."
"SA"	18164769	4	"cancer"	65	71	"Diseases & Disorders"	"statin"	49	55	"Chemicals & Drugs"	"Furthermore, there may be a relationship between statin dose and cancer."
"FA"	17989313	0	"multiple myeloma"	173	189	"Diseases & Disorders"	"BiRD"	0	4	"Chemicals & Drugs"	"BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma."
"FA"	17989313	1	"multiple myeloma"	174	190	"Diseases & Disorders"	"BiRD"	142	146	"Chemicals & Drugs"	"This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma."
"PA"	17989313	10	"multiple myeloma"	107	123	"Diseases & Disorders"	"BiRD"	0	4	"Chemicals & Drugs"	"BiRD is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed multiple myeloma."
"FA"	18299079	1	"endophthalmitis"	102	117	"Diseases & Disorders"	"antibiotics"	71	82	"Chemicals & Drugs"	"Recent prospective studies from Europe suggest the use of intracameral antibiotics for prophylaxis of endophthalmitis, although the studies did not make a comparison with the most common United States prophylaxis techniques."
"PA"	18299079	7	"endophthalmitis"	33	48	"Diseases & Disorders"	"antibiotics"	75	86	"Chemicals & Drugs"	"A multipronged approach to limit endophthalmitis risk is also needed, with antibiotics as only part of the strategy."
"PA"	17668247	3	"nephropathic cystinosis"	38	61	"Diseases & Disorders"	"i.v.) administration of cysteamine hydrochloride"	132	180	"Chemicals & Drugs"	"In this study, a 2-year-old girl with nephropathic cystinosis and severe gastrointestinal dysmotility was treated with intravenous (i.v.) administration of cysteamine hydrochloride (HCl)."
"PA"	18713852	12	"diarrhea"	119	127	"Diseases & Disorders"	"posaconazole"	59	71	"Chemicals & Drugs"	"The most common adverse effects associated with the use of posaconazole include headache, fever, nausea, vomiting, and diarrhea."
"PA"	18713852	9	"oropharyngeal candidiasis"	60	85	"Diseases & Disorders"	"Posaconazole"	0	12	"Chemicals & Drugs"	"Posaconazole is noninferior to fluconazole for treatment of oropharyngeal candidiasis (95% CI -6.6 to 5.0), but necessity for this indication remains unclear, as many other treatment options exist."
"PA"	18713852	8	"aspergillosis"	105	118	"Diseases & Disorders"	"itraconazole"	183	195	"Chemicals & Drugs"	"Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients."
"PA"	18713852	8	"invasive fungal infections"	52	78	"Diseases & Disorders"	"itraconazole"	183	195	"Chemicals & Drugs"	"Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients."
"PA"	18713852	12	"nausea"	97	103	"Diseases & Disorders"	"posaconazole"	59	71	"Chemicals & Drugs"	"The most common adverse effects associated with the use of posaconazole include headache, fever, nausea, vomiting, and diarrhea."
"PA"	18713852	12	"vomiting"	105	113	"Diseases & Disorders"	"posaconazole"	59	71	"Chemicals & Drugs"	"The most common adverse effects associated with the use of posaconazole include headache, fever, nausea, vomiting, and diarrhea."
"PA"	18713852	8	"aspergillosis"	105	118	"Diseases & Disorders"	"posaconazole"	31	43	"Chemicals & Drugs"	"Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients."
"PA"	18713852	8	"invasive fungal infections"	52	78	"Diseases & Disorders"	"posaconazole"	31	43	"Chemicals & Drugs"	"Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients."
"PA"	18713852	12	"headache"	80	88	"Diseases & Disorders"	"posaconazole"	59	71	"Chemicals & Drugs"	"The most common adverse effects associated with the use of posaconazole include headache, fever, nausea, vomiting, and diarrhea."
"SA"	18713852	14	"invasive fungal infection"	100	125	"Diseases & Disorders"	"posaconazole"	14	26	"Chemicals & Drugs"	"At this time, posaconazole should probably be reserved for prophylaxis in patients at high risk for invasive fungal infection, as salvage therapy in refractory or resistant infections, or for patients with intolerance to other therapies."
"SA"	18713852	14	"resistant infections"	163	183	"Diseases & Disorders"	"posaconazole"	14	26	"Chemicals & Drugs"	"At this time, posaconazole should probably be reserved for prophylaxis in patients at high risk for invasive fungal infection, as salvage therapy in refractory or resistant infections, or for patients with intolerance to other therapies."
"PA"	18713852	8	"invasive fungal infections"	52	78	"Diseases & Disorders"	"fluconazole"	167	178	"Chemicals & Drugs"	"Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients."
"PA"	18713852	8	"aspergillosis"	105	118	"Diseases & Disorders"	"fluconazole"	167	178	"Chemicals & Drugs"	"Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients."
"PA"	18713852	7	"aspergillosis"	131	144	"Diseases & Disorders"	"Posaconazole"	0	12	"Chemicals & Drugs"	"Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole."
"PA"	18713852	7	"invasive fungal infections"	69	95	"Diseases & Disorders"	"Posaconazole"	0	12	"Chemicals & Drugs"	"Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole."
"PA"	18713852	9	"oropharyngeal candidiasis"	60	85	"Diseases & Disorders"	"fluconazole"	31	42	"Chemicals & Drugs"	"Posaconazole is noninferior to fluconazole for treatment of oropharyngeal candidiasis (95% CI -6.6 to 5.0), but necessity for this indication remains unclear, as many other treatment options exist."
"PA"	18713852	7	"invasive fungal infections"	69	95	"Diseases & Disorders"	"fluconazole"	274	285	"Chemicals & Drugs"	"Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole."
"PA"	18713852	7	"aspergillosis"	131	144	"Diseases & Disorders"	"fluconazole"	274	285	"Chemicals & Drugs"	"Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole."
"SA"	17499360	5	"cerebellar deficits"	233	252	"Diseases & Disorders"	"succimer"	191	199	"Chemicals & Drugs"	"While some beneficial neuromotor effects of succimer therapy were observed in the present study there remains several unanswered questions such as how long these effects will persist and how succimer therapy modifies lead-associated cerebellar deficits manifesting as perturbations in vestibular and/or proprioception systems for postural balance and functional locomotion."
"FA"	18395883	1	"multiple sclerosis"	65	83	"Diseases & Disorders"	"Long-term immunomodulatory drug"	0	31	"Chemicals & Drugs"	"Long-term immunomodulatory drug (IMD) treatment is now common in multiple sclerosis (MS)."
"PA"	17484031	1	"cardiovascular diseases"	82	105	"Diseases & Disorders"	"tobacco smoke"	22	35	"Chemicals & Drugs"	"It is well known that tobacco smoke exposure is related to the risk of developing cardiovascular diseases and events."
"PA"	17634547	1	"vasomotor symptoms"	92	110	"Diseases & Disorders"	"Tibolone"	0	8	"Chemicals & Drugs"	"Tibolone is a selective tissue estrogenic activity regulator, approved for the treatment of vasomotor symptoms in postmenopausal women."
"FA"	17634547	13	"tumor"	87	92	"Diseases & Disorders"	"tibolone"	31	39	"Chemicals & Drugs"	"In ER+ breast tumors, 2.5 mg/d tibolone given for 14 days has no significant effect on tumor cell proliferation."
"FA"	17634547	13	"ER+ breast tumors"	3	20	"Diseases & Disorders"	"tibolone"	31	39	"Chemicals & Drugs"	"In ER+ breast tumors, 2.5 mg/d tibolone given for 14 days has no significant effect on tumor cell proliferation."
"FA"	17894421	1	"congenital malformations"	117	141	"Diseases & Disorders"	"BZD"	29	32	"Chemicals & Drugs"	"Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts."
"FA"	17894421	1	"orofacial clefts"	156	172	"Diseases & Disorders"	"Benzodiazepines"	12	27	"Chemicals & Drugs"	"Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts."
"FA"	17894421	1	"congenital malformations"	117	141	"Diseases & Disorders"	"Benzodiazepines"	12	27	"Chemicals & Drugs"	"Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts."
"FA"	17894421	11	"preterm birth"	58	71	"Diseases & Disorders"	"BZD"	16	19	"Chemicals & Drugs"	"Maternal use of BZD and/or HBRA may increase the risk for preterm birth and low birth weight and cause neonatal symptoms, but does not appear to have a strong teratogenic potential."
"FA"	17894421	1	"orofacial clefts"	156	172	"Diseases & Disorders"	"BZD"	29	32	"Chemicals & Drugs"	"Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts."
"NA"	19117254	12	"vascular lesions"	100	116	"Diseases & Disorders"	"etonogestrel"	141	153	"Chemicals & Drugs"	"We found no evidence of impaired control of the carbohydrate and lipid metabolism or aggravation of vascular lesions during the two years an etonogestrel implant was used by diabetic women."
"PA"	18230056	0	"infections due to Gram-positive pathogens"	55	96	"Diseases & Disorders"	"Oritavancin"	0	11	"Chemicals & Drugs"	"Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens."
"PA"	18208910	10	"long-term cognitive impairment"	196	226	"Diseases & Disorders"	"ecstasy/cannabis"	42	58	"Chemicals & Drugs"	"Our findings support that ecstasy use, or ecstasy/cannabis synergic effects, are responsible for the sub-clinical deficits observed in ecstasy polydrug users, and provides additional evidence for long-term cognitive impairment owing to ecstasy consumption in the context of polydrug use."
"FA"	18208910	8	"deficits on verbal fluency"	48	74	"Diseases & Disorders"	"ecstasy"	16	23	"Chemicals & Drugs"	"After two years ecstasy users showed persistent deficits on verbal fluency, working memory and processing speed."
"FA"	18208910	7	"deficits on episodic memory"	137	164	"Diseases & Disorders"	"ecstasy"	64	71	"Chemicals & Drugs"	"When ecstasy users were classified according to lifetime use of ecstasy, the more severe users (more than 100 tablets) showed additional deficits on episodic memory."
"FA"	18586644	8	"infections"	171	181	"Diseases & Disorders"	"NaFe-EDTA"	67	76	"Chemicals & Drugs"	"No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects."
"FA"	18586644	8	"iron-deficiency anemia"	116	138	"Diseases & Disorders"	"NaFe-EDTA"	67	76	"Chemicals & Drugs"	"No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects."
"FA"	18586644	8	"iron-deficiency anemia"	116	138	"Diseases & Disorders"	"FeSO4"	49	54	"Chemicals & Drugs"	"No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects."
"FA"	18586644	8	"infections"	171	181	"Diseases & Disorders"	"FeSO4"	49	54	"Chemicals & Drugs"	"No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects."
"FA"	19135998	1	"chronic hepatitis C genotype 4"	88	118	"Diseases & Disorders"	"peginterferon"	132	145	"Chemicals & Drugs"	"Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with peginterferon plus ribavirin."
"PA"	19135998	7	"anemia"	79	85	"Diseases & Disorders"	"ribavirin"	110	119	"Chemicals & Drugs"	"Adverse events were similar across treatment groups except for higher rates of anemia in the groups receiving ribavirin."
"PA"	19135998	1	"chronic hepatitis C genotype 4"	88	118	"Diseases & Disorders"	"ribavirin"	151	160	"Chemicals & Drugs"	"Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with peginterferon plus ribavirin."
"FA"	18058121	1	"spontaneous abortions"	97	118	"Diseases & Disorders"	"radioisotopes of metals and halogen elements"	12	56	"Chemicals & Drugs"	"Exposure to radioisotopes of metals and halogen elements occurring in medical practice may cause spontaneous abortions."
"PA"	18058121	7	"spontaneous abortions"	130	151	"Diseases & Disorders"	"radioisotopes"	60	73	"Chemicals & Drugs"	"For exposure levels within standard recommended guidelines, radioisotopes are far more likely to play a role in the occurrence of spontaneous abortions than X-rays."
"FA"	18058121	5	"spontaneous abortions"	79	100	"Diseases & Disorders"	"radioisotopes"	17	30	"Chemicals & Drugs"	"Women exposed to radioisotopes experienced at least a threefold higher rate of spontaneous abortions than those exposed to X-ray (OR = 3.68, 95% CI = 1.39-9.74, P < 0.01)."
"PA"	17391803	0	"advanced-stage non-small-cell lung cancer"	59	100	"Diseases & Disorders"	"docetaxel"	45	54	"Chemicals & Drugs"	"An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study."
"PA"	19026757	8	"asthma-related deaths"	50	71	"Diseases & Disorders"	"LABA"	12	16	"Chemicals & Drugs"	"Contrarily, LABA showed a significant increase in asthma-related deaths (Relative Risk=3.83; 95% CI, 1.21-12.14)."
"FA"	19026757	5	"asthma exacerbations"	22	42	"Diseases & Disorders"	"corticosteroids"	67	82	"Chemicals & Drugs"	"Primary outcomes were asthma exacerbations (AE) requiring systemic corticosteroids or hospitalization, life-threatening exacerbations and asthma-related deaths."
"PA"	18303032	2	"PTCL"	95	99	"Diseases & Disorders"	"high-dose cyclophosphamide"	126	152	"Chemicals & Drugs"	"Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone."
"PA"	18303032	2	"PTCL"	95	99	"Diseases & Disorders"	"adriamycin"	171	181	"Chemicals & Drugs"	"Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone."
"PA"	18303032	2	"PTCL"	95	99	"Diseases & Disorders"	"cisplatin"	270	279	"Chemicals & Drugs"	"Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone."
"PA"	18303032	2	"PTCL"	95	99	"Diseases & Disorders"	"prednisone"	296	306	"Chemicals & Drugs"	"Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone."
"PA"	18303032	2	"PTCL"	95	99	"Diseases & Disorders"	"vincristine"	198	209	"Chemicals & Drugs"	"Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone."
"PA"	18303032	2	"PTCL"	95	99	"Diseases & Disorders"	"cytarabine"	281	291	"Chemicals & Drugs"	"Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone."
"PA"	18303032	2	"PTCL"	95	99	"Diseases & Disorders"	"etoposide"	259	268	"Chemicals & Drugs"	"Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone."
"PA"	17541882	8	"negative symptoms"	132	149	"Diseases & Disorders"	"ziprasidone"	7	18	"Chemicals & Drugs"	"Plasma ziprasidone levels ranged from 20 ng/mL to 160 ng/mL (mean: 75.8 ng/mL) and were significantly related to the improvement in negative symptoms."
"PA"	17541882	9	"extrapyramidal symptoms"	122	145	"Diseases & Disorders"	"ziprasidone"	75	86	"Chemicals & Drugs"	"The study showed that ziprasidone was effective and tolerable, that use of ziprasidone was characterized by an absence of extrapyramidal symptoms and weight gain, and that no alterations in clinical laboratory tests occurred."
"PA"	19033289	10	"inflammation"	30	42	"Diseases & Disorders"	"bevacizumab"	54	65	"Chemicals & Drugs"	"Characteristic features of an inflammation induced by bevacizumab injection include an early onset with painless loss in VA mostly without conjunctival or ciliary injection."
"PA"	17562245	1	"high-grade non-Hodgkin lymphoma"	179	210	"Diseases & Disorders"	"prednisone"	87	97	"Chemicals & Drugs"	"Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients."
"PA"	17562245	1	"high-grade non-Hodgkin lymphoma"	179	210	"Diseases & Disorders"	"rituximab"	36	45	"Chemicals & Drugs"	"Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients."
"PA"	17562245	1	"high-grade non-Hodgkin lymphoma"	179	210	"Diseases & Disorders"	"doxorubicin"	63	74	"Chemicals & Drugs"	"Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients."
"PA"	17562245	1	"high-grade non-Hodgkin lymphoma"	179	210	"Diseases & Disorders"	"cyclophosphamide"	46	62	"Chemicals & Drugs"	"Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients."
"PA"	17562245	1	"high-grade non-Hodgkin lymphoma"	179	210	"Diseases & Disorders"	"vincristine"	75	86	"Chemicals & Drugs"	"Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients."
"PA"	18512713	9	"lung cancer"	140	151	"Diseases & Disorders"	"methotrexate"	38	50	"Chemicals & Drugs"	"Compared with the general population, methotrexate-treated RA patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and lung cancer."
"PA"	18512713	9	"melanoma"	102	110	"Diseases & Disorders"	"methotrexate"	38	50	"Chemicals & Drugs"	"Compared with the general population, methotrexate-treated RA patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and lung cancer."
"PA"	18512713	9	"non-Hodgkin's lymphoma"	112	134	"Diseases & Disorders"	"methotrexate"	38	50	"Chemicals & Drugs"	"Compared with the general population, methotrexate-treated RA patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and lung cancer."
"FA"	18512713	8	"malignancy"	42	52	"Diseases & Disorders"	"methotrexate"	59	71	"Chemicals & Drugs"	"There was an estimated 50% excess risk of malignancy among methotrexate-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8)."
"PA"	18512713	8	"non-Hodgkin's lymphoma"	263	285	"Diseases & Disorders"	"methotrexate"	59	71	"Chemicals & Drugs"	"There was an estimated 50% excess risk of malignancy among methotrexate-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8)."
"PA"	18512713	8	"lung cancer"	347	358	"Diseases & Disorders"	"methotrexate"	59	71	"Chemicals & Drugs"	"There was an estimated 50% excess risk of malignancy among methotrexate-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8)."
"PA"	18512713	8	"melanoma"	206	214	"Diseases & Disorders"	"methotrexate"	59	71	"Chemicals & Drugs"	"There was an estimated 50% excess risk of malignancy among methotrexate-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8)."
"PA"	18512713	0	"rheumatoid arthritis"	51	71	"Diseases & Disorders"	"methotrexate"	94	106	"Chemicals & Drugs"	"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate."
"PA"	18512713	1	"rheumatoid arthritis"	44	64	"Diseases & Disorders"	"methotrexate"	92	104	"Chemicals & Drugs"	"To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with methotrexate in community practice."
"PA"	18512713	1	"cancer"	13	19	"Diseases & Disorders"	"methotrexate"	92	104	"Chemicals & Drugs"	"To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with methotrexate in community practice."
"PA"	18512713	0	"malignancies"	32	44	"Diseases & Disorders"	"methotrexate"	94	106	"Chemicals & Drugs"	"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate."
"PA"	18512713	0	"melanoma"	13	21	"Diseases & Disorders"	"methotrexate"	94	106	"Chemicals & Drugs"	"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate."
"FA"	18205897	1	"heparin-induced thrombocytopenia type II"	91	131	"Diseases & Disorders"	"Recombinant hirudin"	0	19	"Chemicals & Drugs"	"Recombinant hirudin is used as an alternative anticoagulant, particularly in patients with heparin-induced thrombocytopenia type II."
"PA"	18198174	5	"colitis"	69	76	"Diseases & Disorders"	"dextran sodium sulfate"	38	60	"Chemicals & Drugs"	"Absence of villin predisposes mice to dextran sodium sulfate-induced colitis by promoting apoptosis."
"FA"	18389682	2	"thromboembolism"	210	225	"Diseases & Disorders"	"anticoagulant"	105	118	"Chemicals & Drugs"	"Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral anticoagulant and instituting heparin therapy prior to the planned dental procedure, which can result in thromboembolism and increased morbidity and mortality."
"FA"	18389682	1	"thrombosis"	152	162	"Diseases & Disorders"	"anticoagulant"	109	122	"Chemicals & Drugs"	"Children with prosthetic cardiac valves and other invasive mechanical devices that direct blood flow require anticoagulant medication for prevention of thrombosis."
"PA"	18389682	2	"thromboembolism"	210	225	"Diseases & Disorders"	"heparin"	135	142	"Chemicals & Drugs"	"Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral anticoagulant and instituting heparin therapy prior to the planned dental procedure, which can result in thromboembolism and increased morbidity and mortality."
"PA"	17945482	8	"lung cancer"	213	224	"Diseases & Disorders"	"sutent"	88	94	"Chemicals & Drugs"	"Finally, in non-small cell lung cancer (NSCLC) in patients' progressing on chemotherapy sutent was able to achieve a 10% response rate, a level of activity similar to those documented by other agents approved for lung cancer."
"PA"	17945482	3	"metastatic renal cell carcinoma"	106	137	"Diseases & Disorders"	"sutent"	35	41	"Chemicals & Drugs"	"In several phase I/II/III studies, sutent was found to be effective as second and first line treatment in metastatic renal cell carcinoma (RCC)."
"PA"	17945482	8	"NSCLC"	40	45	"Diseases & Disorders"	"sutent"	88	94	"Chemicals & Drugs"	"Finally, in non-small cell lung cancer (NSCLC) in patients' progressing on chemotherapy sutent was able to achieve a 10% response rate, a level of activity similar to those documented by other agents approved for lung cancer."
"PA"	17945482	5	"GIST"	101	105	"Diseases & Disorders"	"Sutent"	0	6	"Chemicals & Drugs"	"Sutent was also effective as second line treatment in patients with gastrointestinal stromal tumors (GIST) with 8% response rate, 70% stable disease and a 20-month median survival."
"PA"	17945482	7	"breast cancer"	57	70	"Diseases & Disorders"	"sutent"	72	78	"Chemicals & Drugs"	"In addition, a phase II study in multitreated women with breast cancer, sutent demonstrated a moderate activity with 16% clinical benefit."
"PA"	18533797	1	"anemia"	171	177	"Diseases & Disorders"	"Epoetin beta"	0	12	"Chemicals & Drugs"	"Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of solid tumors and lymphoid malignancies."
"FA"	18533797	3	"cancer"	156	162	"Diseases & Disorders"	"epoetin beta"	93	105	"Chemicals & Drugs"	"This once-weekly regimen is generally well tolerated, and studies to date have reported that epoetin beta has a neutral effect on survival of patients with cancer."
"FA"	18533797	0	"anemia"	98	104	"Diseases & Disorders"	"Epoetin beta"	0	12	"Chemicals & Drugs"	"Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia."
"PA"	18790215	5	"immunosuppression"	116	133	"Diseases & Disorders"	"mycophenolate mofetil"	56	77	"Chemicals & Drugs"	"During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for immunosuppression."
"PA"	18790215	5	"immunosuppression"	116	133	"Diseases & Disorders"	"tacrolimus"	28	38	"Chemicals & Drugs"	"During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for immunosuppression."
"PA"	18790215	5	"immunosuppression"	116	133	"Diseases & Disorders"	"methylprednisolone"	83	101	"Chemicals & Drugs"	"During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for immunosuppression."
"PA"	18790215	5	"immunosuppression"	116	133	"Diseases & Disorders"	"cyclosporine"	42	54	"Chemicals & Drugs"	"During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for immunosuppression."
"PA"	17697016	1	"anaemia"	104	111	"Diseases & Disorders"	"interferon"	61	71	"Chemicals & Drugs"	"The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is anaemia."
"PA"	17697016	6	"anaemia"	37	44	"Diseases & Disorders"	"zidovudine"	79	89	"Chemicals & Drugs"	"In multivariate analysis the risk of anaemia was significantly associated with zidovudine (OR, 3.27 95% CI, 1.64-6.54, P = 0.0008) and peg-IFN (OR, 2.35; 95% CI, 1.16-4.57, P = 0.0179)."
"PA"	17697016	8	"anaemia"	47	54	"Diseases & Disorders"	"Zidovudine"	0	10	"Chemicals & Drugs"	"Zidovudine discontinuation could help to avoid anaemia associated with anti-HCV therapy."
"PA"	17697016	7	"anaemia"	12	19	"Diseases & Disorders"	"protease inhibitor"	149	167	"Chemicals & Drugs"	"The risk of anaemia was lower in patients with higher baseline haemoglobin levels (OR, 0.35 95% CI, 0.26-0.49, P < 0.0001) and in patients receiving protease inhibitor-based antiretroviral therapy (OR, 0.51 95% CI, 0.30-0.86, P = 0.0114)."
"PA"	17697016	1	"anaemia"	104	111	"Diseases & Disorders"	"ribavirin"	77	86	"Chemicals & Drugs"	"The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is anaemia."
"PA"	18713156	7	"migraine headache"	97	114	"Diseases & Disorders"	"propranolol"	58	69	"Chemicals & Drugs"	"This study demonstrated that both low-dose topiramate and propranolol could significantly reduce migraine headache frequency, intensity, and duration."
"PA"	18713156	7	"migraine headache"	97	114	"Diseases & Disorders"	"topiramate"	43	53	"Chemicals & Drugs"	"This study demonstrated that both low-dose topiramate and propranolol could significantly reduce migraine headache frequency, intensity, and duration."
"PA"	18713156	5	"headache"	158	166	"Diseases & Disorders"	"topiramate"	14	24	"Chemicals & Drugs"	"Results - The topiramate group showed a reduction in the mean (+/-SD) of monthly migraine frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, headache intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and headache duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001)."
"PA"	18713156	5	"migraine"	81	89	"Diseases & Disorders"	"topiramate"	14	24	"Chemicals & Drugs"	"Results - The topiramate group showed a reduction in the mean (+/-SD) of monthly migraine frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, headache intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and headache duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001)."
"PA"	18077493	0	"hypertension"	73	85	"Diseases & Disorders"	"medium-dose glucocorticoid"	22	48	"Chemicals & Drugs"	"Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis."
"FA"	18077493	0	"rheumatoid arthritis"	103	123	"Diseases & Disorders"	"medium-dose glucocorticoid"	22	48	"Chemicals & Drugs"	"Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis."
"FA"	17547473	7	"cancer"	212	218	"Diseases & Disorders"	"amlodipine"	54	64	"Chemicals & Drugs"	"Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer."
"FA"	17547473	12	"stroke"	83	89	"Diseases & Disorders"	"Dihydropyridine calcium channel antagonists"	0	43	"Chemicals & Drugs"	"Dihydropyridine calcium channel antagonists may exert effects that protect against stroke that are independent of their blood pressure-lowering mechanism."
"PA"	17547473	16	"cardiovascular disease"	369	391	"Diseases & Disorders"	"long-acting dihydropyridine calcium channel antagonists"	197	252	"Chemicals & Drugs"	"Collectively, the cardiovascular benefit, metabolic neutrality and homogeneous blood pressure response illuminated in recent studies, and reviewed here, represent a reaffirmation of the benefit of long-acting dihydropyridine calcium channel antagonists and should serve to help reinforce the critical importance of these agents in the therapeutic armamentarium against cardiovascular disease."
"FA"	17547473	7	"coronary heart disease"	159	181	"Diseases & Disorders"	"amlodipine"	54	64	"Chemicals & Drugs"	"Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer."
"FA"	17547473	7	"gastrointestinal bleeding"	183	208	"Diseases & Disorders"	"amlodipine"	54	64	"Chemicals & Drugs"	"Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer."
"PA"	17547473	7	"cardiovascular events"	75	96	"Diseases & Disorders"	"amlodipine"	54	64	"Chemicals & Drugs"	"Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer."
"FA"	17547473	9	"hypertension"	125	137	"Diseases & Disorders"	"Dihydropyridine calcium channel antagonists"	0	43	"Chemicals & Drugs"	"Dihydropyridine calcium channel antagonists have several noteworthy attributes that merit consideration in the management of hypertension."
"PA"	17726209	5	"stomal varices secondary to portal hypertension"	68	115	"Diseases & Disorders"	"silver nitrate"	174	188	"Chemicals & Drugs"	"All three patients had recurrent admissions for stomal bleeding and stomal varices secondary to portal hypertension and were initially treated with local measures (pressure, silver nitrate, and suture ligation)."
"PA"	17726209	5	"stomal bleeding"	48	63	"Diseases & Disorders"	"silver nitrate"	174	188	"Chemicals & Drugs"	"All three patients had recurrent admissions for stomal bleeding and stomal varices secondary to portal hypertension and were initially treated with local measures (pressure, silver nitrate, and suture ligation)."
"PA"	18975369	7	"gout"	186	190	"Diseases & Disorders"	"allopurinol"	112	123	"Chemicals & Drugs"	"At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function."
"PA"	18975369	7	"hyperuricemia"	168	181	"Diseases & Disorders"	"allopurinol"	112	123	"Chemicals & Drugs"	"At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function."
"PA"	18975369	4	"impaired renal function"	62	85	"Diseases & Disorders"	"febuxostat"	99	109	"Chemicals & Drugs"	"A significantly (P < 0.05) higher percentage of subjects with impaired renal function treated with febuxostat 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11), and 240 mg (3 [60%] of 5) achieved the primary end point compared with those treated with 100 mg of allopurinol (0 [0%] of 10)."
"PA"	18975369	6	"gout flares"	73	84	"Diseases & Disorders"	"allopurinol"	137	148	"Chemicals & Drugs"	"The primary reasons for withdrawal were similar across groups except for gout flares, which were more frequent with febuxostat than with allopurinol."
"PA"	18975369	7	"gout"	186	190	"Diseases & Disorders"	"febuxostat"	22	32	"Chemicals & Drugs"	"At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function."
"PA"	18975369	7	"impaired renal function"	232	255	"Diseases & Disorders"	"febuxostat"	22	32	"Chemicals & Drugs"	"At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function."
"PA"	18975369	7	"hyperuricemia"	168	181	"Diseases & Disorders"	"febuxostat"	22	32	"Chemicals & Drugs"	"At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function."
"PA"	18975369	4	"impaired renal function"	62	85	"Diseases & Disorders"	"allopurinol"	256	267	"Chemicals & Drugs"	"A significantly (P < 0.05) higher percentage of subjects with impaired renal function treated with febuxostat 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11), and 240 mg (3 [60%] of 5) achieved the primary end point compared with those treated with 100 mg of allopurinol (0 [0%] of 10)."
"PA"	18975369	6	"gout flares"	73	84	"Diseases & Disorders"	"febuxostat"	116	126	"Chemicals & Drugs"	"The primary reasons for withdrawal were similar across groups except for gout flares, which were more frequent with febuxostat than with allopurinol."
"PA"	18975369	5	"dizziness"	130	139	"Diseases & Disorders"	"febuxostat"	166	176	"Chemicals & Drugs"	"Proportions of subjects experiencing any adverse event or serious adverse event were similar across groups, although diarrhea and dizziness were more frequent in the febuxostat 240 mg group."
"PA"	18975369	5	"diarrhea"	117	125	"Diseases & Disorders"	"febuxostat"	166	176	"Chemicals & Drugs"	"Proportions of subjects experiencing any adverse event or serious adverse event were similar across groups, although diarrhea and dizziness were more frequent in the febuxostat 240 mg group."
"FA"	17688650	1	"teratogenicity"	16	30	"Diseases & Disorders"	"antiepileptic drugs"	34	53	"Chemicals & Drugs"	"The established teratogenicity of antiepileptic drugs raises important issues in women of child-bearing age."
"PA"	17688650	2	"neural tube defects"	30	49	"Diseases & Disorders"	"antiepileptic drugs"	54	73	"Chemicals & Drugs"	"While the association between neural tube defects and antiepileptic drugs is well recognised, other congenital malformations are known to occur."
"PA"	17688650	2	"congenital malformations"	100	124	"Diseases & Disorders"	"antiepileptic drugs"	54	73	"Chemicals & Drugs"	"While the association between neural tube defects and antiepileptic drugs is well recognised, other congenital malformations are known to occur."
"NA"	18609261	11	"hypogonadism"	54	66	"Diseases & Disorders"	"cyclophosphamide"	83	99	"Chemicals & Drugs"	"Data of our study revealed an unexpected high rate of hypogonadism irrespective of cyclophosphamide use, and subclinical involvement of the testes by the vasculitis itself might be an alternative explanation."
"PA"	18609261	11	"vasculitis"	154	164	"Diseases & Disorders"	"cyclophosphamide"	83	99	"Chemicals & Drugs"	"Data of our study revealed an unexpected high rate of hypogonadism irrespective of cyclophosphamide use, and subclinical involvement of the testes by the vasculitis itself might be an alternative explanation."
"PA"	18560637	7	"autoimmune hepatitis"	56	76	"Diseases & Disorders"	"azathioprine"	39	51	"Chemicals & Drugs"	"The patient was on corticosteroids and azathioprine for autoimmune hepatitis at the time of her presentation."
"PA"	17291222	0	"Pulmonary alveolar proteinosis"	0	30	"Diseases & Disorders"	"sirolimus"	61	70	"Chemicals & Drugs"	"Pulmonary alveolar proteinosis: a rare pulmonary toxicity of sirolimus."
"PA"	17291222	10	"PAP"	0	3	"Diseases & Disorders"	"SRL"	35	38	"Chemicals & Drugs"	"PAP is a very rare complication of SRL therapy with only a few cases described."
"FA"	17291222	3	"nonproductive cough"	82	101	"Diseases & Disorders"	"SRL"	27	30	"Chemicals & Drugs"	"Two years after initiating SRL, she presented complaints of progressive dyspnoea, nonproductive cough, chest pain and low-grade fever of 1 month duration."
"FA"	17291222	3	"chest pain"	103	113	"Diseases & Disorders"	"SRL"	27	30	"Chemicals & Drugs"	"Two years after initiating SRL, she presented complaints of progressive dyspnoea, nonproductive cough, chest pain and low-grade fever of 1 month duration."
"FA"	19100448	9	"leucoencephalopathy"	22	41	"Diseases & Disorders"	"SRL"	82	85	"Chemicals & Drugs"	"The only patient with leucoencephalopathy showed improved neurologic status after SRL conversion."
"PA"	19100448	10	"GI side effects"	41	56	"Diseases & Disorders"	"MMF"	60	63	"Chemicals & Drugs"	"All patients converted to SRL because of GI side effects of MMF showed improvements, and none of those converted because of hyperglycemia experienced improvement."
"PA"	19100448	12	"severe diarrhea"	191	206	"Diseases & Disorders"	"MMF"	214	217	"Chemicals & Drugs"	"We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and neurotoxicity, and in cases of severe diarrhea due to MMF."
"FA"	19100448	4	"gastrointestinal"	201	217	"Diseases & Disorders"	"MMF"	262	265	"Chemicals & Drugs"	"The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%)."
"FA"	19100448	4	"gastrointestinal"	201	217	"Diseases & Disorders"	"mycophenolate mofetil"	239	260	"Chemicals & Drugs"	"The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%)."
"PA"	16944312	10	"hematological side effects"	141	167	"Diseases & Disorders"	"oxcarbazepine"	10	23	"Chemicals & Drugs"	"Moreover, oxcarbazepine can be a valid choice when long-term therapy is required because of the low interaction with other drugs and the low hematological side effects."
"FA"	16944312	9	"perioperative seizures"	118	140	"Diseases & Disorders"	"antiepileptic agents"	76	96	"Chemicals & Drugs"	"Our data showed that oxcarbazepine can be a good alternative to traditional antiepileptic agents in the prevention of perioperative seizures being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors."
"PA"	16944312	9	"perioperative seizures"	118	140	"Diseases & Disorders"	"oxcarbazepine"	21	34	"Chemicals & Drugs"	"Our data showed that oxcarbazepine can be a good alternative to traditional antiepileptic agents in the prevention of perioperative seizures being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors."
"FA"	16944312	3	"perioperative seizures"	94	116	"Diseases & Disorders"	"antiepileptic agents"	51	71	"Chemicals & Drugs"	"Furthermore, the efficacy of the new generation of antiepileptic agents in the prophylaxis of perioperative seizures has not been assessed so far."
"SA"	17244684	1	"GVHD"	127	131	"Diseases & Disorders"	"oral beclomethasone dipropionate"	30	62	"Chemicals & Drugs"	"We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea."
"FA"	17244684	1	"gastrointestinal graft-versus-host disease"	83	125	"Diseases & Disorders"	"BDP"	64	67	"Chemicals & Drugs"	"We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea."
"PA"	17244684	9	"relapses of gastrointestinal GVHD"	18	51	"Diseases & Disorders"	"prednisone"	74	84	"Chemicals & Drugs"	"Oral BDP prevents relapses of gastrointestinal GVHD following tapering of prednisone; survival is statistically significantly better among patients receiving BDP."
"PA"	17244684	9	"relapses of gastrointestinal GVHD"	18	51	"Diseases & Disorders"	"BDP"	158	161	"Chemicals & Drugs"	"Oral BDP prevents relapses of gastrointestinal GVHD following tapering of prednisone; survival is statistically significantly better among patients receiving BDP."
"PA"	18398094	12	"edema"	28	33	"Diseases & Disorders"	"TAC"	121	124	"Chemicals & Drugs"	"Grade 3 or 4 leukopenia and edema and various grade 1 or 2 adverse events were more frequent in patients receiving eight TAC cycles than in those receiving six cycles."
"PA"	18398094	12	"leukopenia"	13	23	"Diseases & Disorders"	"TAC"	121	124	"Chemicals & Drugs"	"Grade 3 or 4 leukopenia and edema and various grade 1 or 2 adverse events were more frequent in patients receiving eight TAC cycles than in those receiving six cycles."
